Results 201 to 210 of about 5,958,077 (318)

Shona Wilson, 1998 [picture] /

, 1998
Title from caption.; Inscriptions: Smaller print: "Shona Wilson 1998" - in ink on reverse l.l. corner. "Photograph by Greg Weight" - in ink on reverse l.r. corner. Larger print: none.; Two prints from the same negative.; Condition: good.
Weight, Greg, 1946-
core  

Epigenetic silencing of the liver‐specific lncRNA LUNAR promotes liver cancer progression via NOTCH activation

Molecular Oncology, EarlyView.
LUNAR is a liver‐specific long noncoding RNA (lncRNA) that is highly expressed in normal liver but becomes epigenetically silenced in hepatocellular carcinoma through promoter hypermethylation. Loss of LUNAR is associated with NOTCH activation, epithelial–mesenchymal transition, and metastasis, whereas restoring LUNAR restrains metastatic progression ...
Se Ha Jang, Hyung Seok Kim, Geum Ok Baek, Moon Gyeong Yoon, Su In Lee, Jee‐Yeong Jeong, Ji Eun Han, Soon Sun Kim, Jae Youn Cheong, Jung Woo Eun   +9 more
wiley   +1 more source

Effect of Intermittent Fasting on Weight Loss in Overweight and Obese Adults: A Systematic Review of Clinical Trials. [PDF]

Food Sci Nutr
Manzoor HMI, Sultan MT, Hameed A, Noman AM, Khalid M, Kazmi M, Sohail A, Ramadan MF, Zongo E, Rahim MA, Al-Asmari F.   +10 more
europepmc   +1 more source

Weights and weighting. [II.] [PDF]

Časopis pro pěstování matematiky a fysiky, 1900
openaire   +1 more source

Translating whole‐genome doubling into precision medicine in cancer

Molecular Oncology, EarlyView.
Whole‐genome doubling creates a WGD‐positive tumor state characterized by persistent chromosomal instability, karyotypic diversification, and cellular stress. These same biological pressures drive aggressive tumor evolution while exposing therapeutic vulnerabilities, providing a rationale for WGD‐informed precision medicine. Whole‐genome doubling (WGD)
Sejung Lee, Junghyeok Lim, Jinhyuk Bhin
wiley   +1 more source

Why Do We Lose Bone During Weight Loss: Can It Be Prevented? [PDF]

Curr Osteoporos Rep
Shapses SA, McGuire BD.
europepmc   +1 more source

CEACAM1 participation in breast cancer progression

Molecular Oncology, EarlyView.
In invasive breast cancer (BC), CEACAM1 shifts from an apical to a uniform membranous/cytoplasmic pattern, or is lost, as tumors dedifferentiate, inversely tracking the Ki‐67 proliferative index. In MCF‐7 cells, only CEACAM1‐4L suppresses proliferation, repressing cell cycle and growth factor genes.
Mykola Lyndin, Irina Kube‐Golovin, Anatolii Romaniuk, Gunther Wennemuth   +3 more
wiley   +1 more source

Weight trajectories and kidney function in early childhood. [PDF]

J Bras Nefrol
Dias M, Mosca S, Almeida LL, Guerra A, Azevedo A, Santos AC, Schaefer F, Afonso AC, Correia-Costa L.   +8 more
europepmc   +1 more source

Pharmacological chromatin remodeling enhances response to estrogen therapy in ER+ breast cancer

Molecular Oncology, EarlyView.
Estrogen therapy elicits clinical benefit in ~ 30% of patients with endocrine‐resistant estrogen receptor (ER)‐positive breast cancer. Based on findings that ER transcriptional activation underlies response to estrogen therapy, we tested the effects of epigenetic dysregulation via pharmacological inhibition of histone deacetylases (HDACi).
Anneka L. Johnson Thomas, Barbara Karakyriakou, Patricia C. Muskus, Alyssa M. Roberts, Justin Rendleman, Alexa Warren, Hanxu Lu, Kimberly A. Birmingham, Malone K. Friedman, Abigail E. Goen, Huijuan Yang, Owen M. Wilkins, Fred W. Kolling, Eugene Demidenko, Julie M. Jorns, Brock C. Christensen, Todd W. Miller   +16 more
wiley   +1 more source

Early weight loss predicts poorer prognosis and highlights limitations of predictive energy equations in amyotrophic lateral sclerosis. [PDF]

J Neurol
Sewell-Green AR, Capstick R, Holdom CJ, Matthews-Rensch K, Cameron J, McCombe PA, Henderson RD, Ngo ST, Steyn FJ.   +8 more
europepmc   +1 more source